Avid Bioservices Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results. Also, RBC Capital Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $12.
Avid Bioservices Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results. Also, RBC Capital Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $12.
avid bioservices股票在公司报告超出预期的Q1调整后的每股收益结果后交易上涨。此外，RBC Capital维持股票的outperform评级，并将目标股价从$8上调至$12。
Avid Bioservices Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Adjusted EPS Results. Also, RBC Capital Maintained an Outperform Rating on the Stock and Raised Its Price Target From $8 to $12.
Avid Bioservices公布的第一季度调整后每股收益好于预期后，该公司股价走高。此外，加拿大皇家银行资本维持该股跑赢大盘的评级，并将其目标股价从8美元上调至12美元。
资讯热榜
更新时间